ID CMB HC.PH.BIO.CMB
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Vericel Corp | VCEL | United States of America | $1.85B | 1,689 |
| Innoviva, Inc. | INVA | United States of America | $1.66B | 1,602 |
| Immunocore Holdings plc | IMCR | United Kingdom | $1.44B | 314 |
| OCULAR THERAPEUTIX, INC | OCUL | United States of America | $1.80B | 910 |
| Harmony Biosciences Holdings, Inc. | HRMY | United States of America | $1.60B | 536 |
| Nuvation Bio Inc. | NUVB | United States of America | $1.68B | 434 |
| HANALL BIOPHARMA CO.,LTD | 009420 | South Korea | $1.98B | 1,481 |
| Pharma Mar S.A. | PHM | Spain | $1.39B | 400 |
| IOVANCE BIOTHERAPEUTICS, INC. | IOVA | United States of America | $2.23B | 994 |
| ARDELYX, INC. | ARDX | United States of America | $1.34B | 1,186 |
| NOVAVAX INC | NVAX | United States of America | $1.46B | 1,640 |
| Pharming Group N.V. | PHARM | Netherlands | $1.01B | 896 |
| DAEWOONG PHARMA | 069620 | South Korea | $910.06M | 1,298 |
| Xeris Biopharma Holdings, Inc. | XERS | United States of America | $1.33B | 370 |
| COLLEGIUM PHARMACEUTICAL, INC | COLL | United States of America | $1.14B | 916 |
| Idorsia Ltd | IDIA | Switzerland | $1.91B | 389 |
| KalVista Pharmaceuticals, Inc. | KALV | United States of America | $1.44B | 909 |
| Pacira BioSciences, Inc. | PCRX | United States of America | $972.28M | 1,331 |
| GERON CORP | GERN | United States of America | $967.22M | 1,563 |
| UroGen Pharma Ltd. | URGN | Israel | $1.33B | 633 |
| MedinCell S.A. | MEDCL | France | $1.13B | 636 |
| Basilea Pharmaceutica AG | BSLN | Switzerland | $881.29M | 435 |
| ALLERGY THERAPEUTICS PLC | AGY | United Kingdom | $870.27M | 419 |
| Phathom Pharmaceuticals, Inc. | PHAT | United States of America | $825.02M | 541 |
| ARS Pharmaceuticals, Inc. | SPRY | United States of America | $952.32M | 569 |
| ONENESS BIOTECH CO., LTD. | 4743 | Taiwan | $764.62M | 2,024 |
| Theravance Biopharma, Inc. | TBPH | Cayman Islands | $785.78M | 1,163 |
| MANNKIND CORP | MNKD | United States of America | $1.10B | 2,072 |
| Chong Kun Dang Pharmaceutical Corp. | 185750 | South Korea | $754.64M | 830 |
| LEXICON PHARMACEUTICALS, INC. | LXRX | United States of America | $986.12M | 1,394 |
| Esperion Therapeutics, Inc. | ESPR | United States of America | $703.66M | 1,024 |
| DAEWOONG CO.,LTD | 003090 | South Korea | $674.57M | 1,611 |
| SINOVAC BIOTECH LTD | SVA | Antigua and Barbuda | $642.44M | 577 |
| IRONWOOD PHARMACEUTICALS INC | IRWD | United States of America | $597.55M | 1,436 |
| ZEVRA THERAPEUTICS, INC. | ZVRA | United States of America | $547.19M | 913 |
| Valneva SE | VLA | France | $492.67M | 1,888 |
| KAMADA LTD | KMDA | United States of America | $512.79M | 536 |
| RIGEL PHARMACEUTICALS INC | RIGL | United States of America | $568.38M | 1,471 |
| Aquestive Therapeutics, Inc. | AQST | United States of America | $524.45M | 751 |
| Kamada Ltd. | KMDA | Israel | $478.95M | 2,978 |
| ADC Therapeutics SA | ADCT | United States of America | $164.08M | 516 |
| Verastem, Inc. | VSTM | United States of America | $375.22M | 1,084 |
| TaiMed Biologics Inc. | 4147 | Taiwan | $476.56M | 1,865 |
| Emergent BioSolutions Inc. | EBS | United States of America | $406.40M | 1,823 |
| Newron Pharmaceuticals S.p.A. | NWRN | Italy | $322.06M | 401 |
| X4 Pharmaceuticals, Inc | XFOR | United States of America | $385.50M | 848 |
| SIGA TECHNOLOGIES INC | SIGA | United States of America | $311.28M | 1,087 |
| Akebia Therapeutics, Inc. | AKBA | United States of America | $250.90M | 929 |
| Autolus Therapeutics plc | AUTL | United Kingdom | $367.28M | 404 |
| Hansa Biopharma | HNSA | Sweden | $364.60M | 667 |
Other names for this activity, and where neighboring activities go instead.
No aliases listed.
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Also preclinical, drug developer
https://financialfilings.com/oics/CMB/
This page is keyed by the class ID CMB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.